SCI Pharmtech, Inc. (TPE:4119)

Market Cap	7.97B
Revenue (ttm)	1.57B
Net Income (ttm)	521.91M
Shares Out	119.51M
EPS (ttm)	4.35
PE Ratio	15.33
Forward PE	n/a
Dividend	1.50 (2.25%)
Ex-Dividend Date	Jul 1, 2025

Volume	94,935
Average Volume	97,205
Open	66.80
Previous Close	66.70
Day's Range	66.40 - 66.90
52-Week Range	63.50 - 98.80
Beta	-0.10
RSI	33.72
Earnings Date	Aug 8, 2025

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2024, SCI Pharmtech's revenue was 1.52 billion, an increase of 26.54% compared to the previous year's 1.20 billion. Earnings were 534.68 million, an increase of 81.42%.